EU Medicines Agency Panel Recommends New Indication for Novartis' Consentyx Drug

MT Newswires · 2d ago
07:56 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion recommending a change to the marketing authorization of Novartis' (NOVN.SW) Cosentyx. The new indication covers adolescents aged 12 years and older with active moderate to severe hidradenitis suppurativa who have had an inadequate response to conventional systemic therapy, according to a Friday notice. The recommendation remains subject to a final decision by the European Commission.